The 17 references in paper Georgii Khachatryan Rubenovich, Vladislav Dombrovskii Sergeevich, Георгий Хачатрян Рубенович, Владислав Домбровский Сергеевич (2015) “Систематический обзор литературы о клинической эффективности и безопасности алоглиптина в сравнении с вилдаглиптином, линаглиптином, саксаглиптином и ситаглиптином у взрослых пациентов с сахарным диабетом 2-го типа // SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS” / spz:neicon:pharmacoeconomics:y:2015:i:2:p:55-61

1
Dedov I., Shestakova M., Galstyan G. et al. Sakharnyi diabet.
(check this in PDF content)
2
15; 18 (1S): 1-112. DOI: 10.14341/DM20151S1-112. 2. Rebrova O., Goryainov S. Meditsinskie tekhnologii. Otsenka i vybor. 2013; 4 (14): 8-14.
(check this in PDF content)
3
Rebrova O., Fedyaeva V., Khachatryan G. Meditsinskie tekhnologii. Otsenka i vybor. 2015; 1 (19): 9-17.
(check this in PDF content)
4
Rosstat. Incidence of socially significant illnesses. URL: http:// www.gks.ru/free_doc/new_site/population/zdrav/zdr2-2.xls (accessed 15.07.15).
(check this in PDF content)
5
American Diabetes Association. Standards of medical care in diabetes 2015. Diabetes Care. Jan 2015; 38 (1).
(check this in PDF content)
6
Bucher H.C., Gordon H.G., Lauren E.G., Walter S.D. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. J Clin Epidemiol. 1997 Jun; 50 (6): 683-91.
(check this in PDF content)
7
Craddy P., Palin H.J., Johnson K.I. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014 Jun; 5 (1): 1-41. DOI: 10.1007/s13300-014-0061-3. Epub 2014 Mar 25.
(check this in PDF content)
8
Flodgren G., Eccles M.P., Shepperd S. et al. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes. Cochrane Database of Systematic Reviews. 2011; 7. Art. No.: CD009255. DOI: 10.1002/14651858.CD009255.
(check this in PDF content)
9
Green J.B., Bethel M.A., Armstrong P.W. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16; 373 (3): 232-42. DOI: 10.1056/NEJMoa1501352. Epub 2015 Jun 8.
(check this in PDF content)
10
Jansen J.P., Trikalinos T., Cappelleri J.C. et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014 Mar; 17 (2): 157-73. DOI: 10.1016/j. jval.2014.01.004.
(check this in PDF content)
11
Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014 Jul; 24 (7): 689-97. DOI: 10.1016/j.numecd.2014.01.017. Epub 2014 Mar 5.
(check this in PDF content)
12
Scirica B.M., Bhatt D.L., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3; 369 (14): 1317-26. DOI: 10.1056/ NEJMoa1307684. Epub 2013 Sep 2.
(check this in PDF content)
13
Scirica B.M., Braunwald E., Raz I. et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 Oct 28; 130 (18): 1579-88. DOI: 10.1161/CIRCULATIONAHA.114.010389. Epub 2014 Sep 4.
(check this in PDF content)
14
Shea B.J., Grimshaw J.M., Wells G.A. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007 Feb 15; 7: 10.
(check this in PDF content)
15
Song F., Altman D.G., Glenny A.M., et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta analyses. BMJ. 2003 Mar 1; 326 (7387): 472.
(check this in PDF content)
16
White W.B., Cannon C.P., Heller S.R. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3; 369 (14): 1327-35. DOI: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.
(check this in PDF content)
17
Zannad F., Cannon C.P., Cushman W.C. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385 (9982): 2067-76. DOI: 10.1016/S01406736(14)62225-X. Epub 2015 Mar 10.
(check this in PDF content)